BLOCK HIV/HCVBringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men: a systematic review and meta-analysis.
Hagan H, et al. AIDS. 2015;29(17):2335-2345.
Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012.
Suryaprasad AG, et al. Clin Infect Dis. 2014;59(10):1411-1419.
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination.
Virlogeux V, et al. BMC Med. 2017;15(1):217.
Debes JD, et al. J Clin Transl Hepatol. 2016;4(4):328-335.
Rallón N, et al. PLoS One. 2017;12(3):e0173943.
Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.
Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection.
Allyn PR, et al. Int J STD AIDS. 2018;29(4):334-340.
Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact.
MacGregor L, et al. Int J Epidemiol. 2017;46(5):1582-1592.
HIV/HCV co-infection: new guidelines, opportunities & challenges with the incarcerated population in the U.S.
Fisher N. HIV Specialist. 2017;9(1):16-19.
Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.
Oramasionwu CU, et al. AIDS Patient Care STDS. 2014;28(5):228-239.
Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice.
Bhattacharya D, et al. Clin Infect Dis. 2017;64(12):1711-1720.
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G, et al. Int J Infect Dis. 2017;62:64-71.
Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection.
Collins LF, et al. Open Forum Infect Dis. 2017;5(1):ofx264.
High hepatitis C cure rates among black and nonblack human immunodeficiency virus–infected adults in an urban center.
Falade-Nwulia O, et al. Hepatology. 2017;66(5):1402-1412.
Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection.
Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.
Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients.
Mínguez C, et al. AIDS. 2018;32(3):337-346.
Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study.
Rockstroh JK, et al. Clin Infect Dis. 2018. (Epub ahead of print).
Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study.
Younossi ZM, et al. Liver Int. 2017;37(12):1796-1804.
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection.
Zeuzem S, et al. J Gastroenterol. 2018;53(5):679-688.
Chhatwal J, et al. Aliment Pharmacol Ther. 2018;47(7):1023-1031.
Falade-Nwulia O, Sulkowski M. J Hepatol. 2017;66(2):267-269.
Grebely J, Dore GJ. Clin Liver Dis. 2017;9(4):77-80.
Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV.
Young J, et al. Clin Infect Dis. 2017;64(9):1154-1162.
The PCPs Role in Preventing HIV
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist